This indicates that SSRI exposure "may be" associated with an increased risk of PPHN
, but the magnitude of that risk--if present--is smaller than previous studies have reported, Krista F.
The authors of the second study suggest that the incidence of PPHN
associated with SSRI exposure in late pregnancy approaches 1%.
Eric Buck, region president of PPHN
says, "Working together with The Principal was a natural fit because their health and technology expertise fits well with our competitive statewide provider network, physician and hospital pricing, and localized medical management and customer service.
An early study published in February 2006 reported a sixfold greater risk of PPHN
among newborns whose mothers took an SSRI after 20 weeks' gestation, compared with newborns whose mothers did not take an SSRI (N.
While ECMO is probably the best treatment for PPHN
due to the fact that it bypasses the lungs completely, allowing for healing time, it is very expensive and imposes higher risk factors than other forms of treatment.
One wonders whether women without an adverse outcome may be reluctant to disclose use of an antidepressant during pregnancy, compared with those with an adverse outcome as serious as PPHN
Chambers of the University of California, San Diego, and her associates investigated the association between SSRI use and PPHN
in 377 women whose infants had PPHN
and 836 matched controls.
is a life-threatening condition in which a newborn=s blood continues to be shunted away from, rather than be oxygenated by the lung.
Gideon Koren, professor of pediatrics, pharmacology, pharmacy, medicine, and medical genetics at the University of Toronto, commented in an interview, "I support FDA's hesitation in confirming causation of SSRIs in causing PPHN
Fourteen cases of PPHN
were noted among women taking SSRIs after the 20th week of gestation, compared with six cases in control infants (adjusted odds ratio 6.
informs health care practitioners about the recall and advises them to immediately stop using Enteryx and return unused products to the manufacturer.
While more recent results from studies suggest that risk for PPHN
following SSRI use during pregnancy is far less than originally estimated, results in the literature consistently indicate that about 25%-30% of infants exposed to SSRIs late in pregnancy manifest symptoms of this transient jitteriness and "poor neonatal adaptation," with associated symptoms of restlessness, myoclonus, and tachypnea.